These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25305134)

  • 1. Report of a 7 year case-control study of continuous intraperitoneal insulin infusion and subcutaneous insulin therapy among patients with poorly controlled type 1 diabetes mellitus: favourable effects on hypoglycaemic episodes.
    van Dijk PR; Logtenberg SJ; Groenier KH; Gans RO; Bilo HJ; Kleefstra N
    Diabetes Res Clin Pract; 2014 Nov; 106(2):256-63. PubMed ID: 25305134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post-trial follow-up.
    van Dijk PR; Logtenberg SJ; Groenier KH; Gans RO; Kleefstra N; Bilo HJ
    BMC Endocr Disord; 2014 Apr; 14():30. PubMed ID: 24708696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal versus subcutaneous insulin therapy in the treatment of type 1 diabetes mellitus.
    van Dijk PR; Logtenberg SJ; Hendriks SH; Groenier KH; Feenstra J; Pouwer F; Gans RO; Kleefstra N; Bilo HJ
    Neth J Med; 2015 Nov; 73(9):399-409. PubMed ID: 26582805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous intraperitoneal insulin infusion versus subcutaneous insulin therapy in the treatment of type 1 diabetes: effects on glycemic variability.
    van Dijk PR; Groenier KH; DeVries JH; Gans RO; Kleefstra N; Bilo HJ; Logtenberg SJ
    Diabetes Technol Ther; 2015 Jun; 17(6):379-84. PubMed ID: 25856045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. After 6years of intraperitoneal insulin administration IGF-I concentrations in T1DM patients are at low-normal level.
    van Dijk PR; Logtenberg SJ; Chisalita SI; Hedman CA; Groenier KH; Gans RO; Kleefstra N; Arnqvist HJ; Bilo HJ
    Growth Horm IGF Res; 2015 Dec; 25(6):316-9. PubMed ID: 26336814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycaemic control, health status and treatment satisfaction with continuous intraperitoneal insulin infusion.
    Logtenberg SJ; van Ballegooie E; Israêl-Bultman H; van Linde A; Bilo HJ
    Neth J Med; 2007 Feb; 65(2):65-70. PubMed ID: 17379931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion.
    Liebl A; Hoogma R; Renard E; Geelhoed-Duijvestijn PH; Klein E; Diglas J; Kessler L; Melki V; Diem P; Brun JM; Schaepelynck-Bélicar P; Frei T;
    Diabetes Obes Metab; 2009 Nov; 11(11):1001-8. PubMed ID: 19740082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial.
    Logtenberg SJ; Kleefstra N; Houweling ST; Groenier KH; Gans RO; van Ballegooie E; Bilo HJ
    Diabetes Care; 2009 Aug; 32(8):1372-7. PubMed ID: 19429874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia.
    van Dijk PR; Logtenberg SJ; Gans RO; Bilo HJ; Kleefstra N
    Clin Endocrinol (Oxf); 2014 Oct; 81(4):488-97. PubMed ID: 25041605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients.
    Oskarsson PR; Lins PE; Backman L; Adamson UC
    Diabetes Metab; 2000 Apr; 26(2):118-24. PubMed ID: 10804326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different Effects of Intraperitoneal and Subcutaneous Insulin Administration on the GH-IGF-1 Axis in Type 1 Diabetes.
    van Dijk PR; Logtenberg SJ; Chisalita SI; Hedman CA; Groenier KH; Gans RO; Kleefstra N; Arnqvist HJ; Bilo HJ
    J Clin Endocrinol Metab; 2016 Jun; 101(6):2493-501. PubMed ID: 27115061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A New Optimized Percutaneous Access System for CIPII.
    Garcia-Verdugo R; Erbach M; Schnell O
    J Diabetes Sci Technol; 2017 Jul; 11(4):814-821. PubMed ID: 28654300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the DIABRASPORT randomized study.
    Franc S; Daoudi A; Pochat A; Petit MH; Randazzo C; Petit C; Duclos M; Penfornis A; Pussard E; Not D; Heyman E; Koukoui F; Simon C; Charpentier G
    Diabetes Obes Metab; 2015 Dec; 17(12):1150-7. PubMed ID: 26264812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
    Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological effects of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: A systematic review and meta-analysis.
    Dirnena-Fusini I; Åm MK; Fougner AL; Carlsen SM; Christiansen SC
    PLoS One; 2021; 16(4):e0249611. PubMed ID: 33848314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
    Sulli N; Shashaj B
    Diabet Med; 2006 Aug; 23(8):900-6. PubMed ID: 16911629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies.
    Lassmann-Vague V; Belicar P; Alessis C; Raccah D; Vialettes B; Vague P
    Diabet Med; 1996 Dec; 13(12):1051-5. PubMed ID: 8973887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
    Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
    Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.
    Pozzilli P; Battelino T; Danne T; Hovorka R; Jarosz-Chobot P; Renard E
    Diabetes Metab Res Rev; 2016 Jan; 32(1):21-39. PubMed ID: 25865292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.